Previous close | 4.9000 |
Open | 4.9000 |
Bid | 5.0000 |
Ask | 8.0000 |
Strike | 12.00 |
Expiry date | 2024-10-18 |
Day's range | 4.9000 - 4.9000 |
Contract range | N/A |
Volume | |
Open interest | 5 |
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.